Abstract
Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Dyslipidemia is one of the main risk factors leading to atherosclerosis. Moreover, there is evidence for a role of oxidation in linking lipids and inflammation to development and progression of atherosclerosis. Current therapeutic approaches with lipid-lowering agents, such as statins, fail to protect more than half of patients from cardiovascular events. Therefore, there is a need for additional and alternative treatment options. There are several novel molecules undergoing preclinical or clinical development for the treatment of dyslipidemia or against distinct pathways which contribute to the development of atherosclerosis. Novel squalene synthase inhibitors with significant cholesterollowering and antiatherosclerotic properties are under development. Targeting the production of apolipoprotein B-100 with an antisense oligonucleotide is another interesting approach for lowering low density lipoprotein(LDL)-cholesterol levels. Raising high density lipoprotein( HDL)-cholesterol levels or improving its antiatherosclerotic properties constitute additional attractive targets for protection against CVD. Such compounds include the cholesteryl ester transfer protein inhibitors, HDL-derived proteins, and mimetic peptides/ lipids. Direct targeting of atherosclerosis remains a challenge. Molecules against oxidation and/or inflammation could be beneficial in reducing atherosclerosis. Other targets involved in distinct pathways of atherosclerosis include the lipoprotein-associated phospholipase A2, 5-lipoxygenase-activating protein, acyl-CoA:cholesterol acyltransferase, chemokine receptors, and protein kinases. In conclusion, there are several promising novel therapeutic approaches for dyslipidemia and atherosclerosis under development which are expected to be of great benefit for patients at risk of CVD.
Keywords: Novel molecules, dyslipidemia, atherosclerosis, cholesterol-lowering agents, squalene synthase inhibitors, antisense oligonucleotides, HDL-modifying agents, anti-atherosclerotic agents
Current Medicinal Chemistry
Title: Novel Molecules Targeting Dyslipidemia and Atherosclerosis
Volume: 15 Issue: 8
Author(s): A. Tavridou and V. G. Manolopoulos
Affiliation:
Keywords: Novel molecules, dyslipidemia, atherosclerosis, cholesterol-lowering agents, squalene synthase inhibitors, antisense oligonucleotides, HDL-modifying agents, anti-atherosclerotic agents
Abstract: Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Dyslipidemia is one of the main risk factors leading to atherosclerosis. Moreover, there is evidence for a role of oxidation in linking lipids and inflammation to development and progression of atherosclerosis. Current therapeutic approaches with lipid-lowering agents, such as statins, fail to protect more than half of patients from cardiovascular events. Therefore, there is a need for additional and alternative treatment options. There are several novel molecules undergoing preclinical or clinical development for the treatment of dyslipidemia or against distinct pathways which contribute to the development of atherosclerosis. Novel squalene synthase inhibitors with significant cholesterollowering and antiatherosclerotic properties are under development. Targeting the production of apolipoprotein B-100 with an antisense oligonucleotide is another interesting approach for lowering low density lipoprotein(LDL)-cholesterol levels. Raising high density lipoprotein( HDL)-cholesterol levels or improving its antiatherosclerotic properties constitute additional attractive targets for protection against CVD. Such compounds include the cholesteryl ester transfer protein inhibitors, HDL-derived proteins, and mimetic peptides/ lipids. Direct targeting of atherosclerosis remains a challenge. Molecules against oxidation and/or inflammation could be beneficial in reducing atherosclerosis. Other targets involved in distinct pathways of atherosclerosis include the lipoprotein-associated phospholipase A2, 5-lipoxygenase-activating protein, acyl-CoA:cholesterol acyltransferase, chemokine receptors, and protein kinases. In conclusion, there are several promising novel therapeutic approaches for dyslipidemia and atherosclerosis under development which are expected to be of great benefit for patients at risk of CVD.
Export Options
About this article
Cite this article as:
Tavridou A. and Manolopoulos G. V., Novel Molecules Targeting Dyslipidemia and Atherosclerosis, Current Medicinal Chemistry 2008; 15 (8) . https://dx.doi.org/10.2174/092986708783955482
DOI https://dx.doi.org/10.2174/092986708783955482 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes
Current Neurovascular Research Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia
Current Pharmaceutical Design Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics The Anabolic Androgenic Steroid Testosterone Propionate Decreases Recognition Memory in Adult Male Rats
Current Psychopharmacology Clinical Pharmacotherapy and Drug Development for Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Multi-Modality Cardiac Imaging in Interventional Cardiology
Current Medical Imaging Circulating Endothelial Progenitor Cells as Biomarkers for Prediction of Cardiovascular Outcomes
Current Medicinal Chemistry Subject Index To Volume 8
Current Pharmaceutical Design Depression in Older Persons with Mobility Limitations
Current Pharmaceutical Design Antibacterial Activities of Flavonoids: Structure-Activity Relationship and Mechanism
Current Medicinal Chemistry Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Current Topics in Medicinal Chemistry Antiplatelet Effects of Bioactive Compounds Present in Tomato Pomace
Current Drug Targets Adonis sp., Convallaria sp., Strophanthus sp., Thevetia sp., and Leonurus sp. - Cardiotonic Plants with Known Traditional Use and a Few Preclinical and Clinical Studies
Current Pharmaceutical Design Key Sites for P2X Receptor Function and Multimerization: Overview of Mutagenesis Studies on a Structural Basis
Current Medicinal Chemistry